Viser 101 - 105 av 105 resultater
Tid Selskap Tittel Sektor Kategori
28 Nov 2023
07:00 CET
ARGENX SE argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia 20103010 Biotechnology Other subject
16 Nov 2023
13:40 CET
ARGENX SE argenx Announces European Commission Approval of Subcutaneous VYVGART® (efgartigimod alfa) for Generalized Myasthenia Gravis 20103010 Biotechnology Other subject
01 Nov 2023
07:00 CET
ARGENX SE argenx to Present at Upcoming Investor Conferences 20103010 Biotechnology Other subject
01 Nov 2023
07:00 CET
ARGENX SE argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions 20103010 Biotechnology Other subject
31 Oct 2023
07:00 CET
ARGENX SE argenx Reports Third Quarter 2023 Financial Results and Provides Business Update 20103010 Biotechnology Other subject